- Home
- STTK vs PESI Comparison
STTK vs PESI Comparison
Compare STTK & PESI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- PESI
- Stock Information
- Founded
- STTK 2016
- PESI 1990
- Country
- STTK United States
- PESI United States
- Employees
- STTK N/A
- PESI N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- PESI Environmental Services
- Sector
- STTK Health Care
- PESI Industrials
- Exchange
- STTK Nasdaq
- PESI Nasdaq
- Market Cap
- STTK 56.8M
- PESI 191.9M
- IPO Year
- STTK 2020
- PESI 1992
- Fundamental
- Price
- STTK $1.12
- PESI $10.68
- Analyst Decision
- STTK Hold
- PESI Strong Buy
- Analyst Count
- STTK 3
- PESI 1
- Target Price
- STTK $2.00
- PESI $18.00
- AVG Volume (30 Days)
- STTK 182.2K
- PESI 139.0K
- Earning Date
- STTK 02-27-2025
- PESI 03-12-2025
- Dividend Yield
- STTK N/A
- PESI N/A
- EPS Growth
- STTK N/A
- PESI N/A
- EPS
- STTK N/A
- PESI N/A
- Revenue
- STTK $6,435,000.00
- PESI $67,134,000.00
- Revenue This Year
- STTK $313.04
- PESI N/A
- Revenue Next Year
- STTK N/A
- PESI $52.66
- P/E Ratio
- STTK N/A
- PESI N/A
- Revenue Growth
- STTK 382.75
- PESI N/A
- 52 Week Low
- STTK $0.94
- PESI $7.63
- 52 Week High
- STTK $11.76
- PESI $16.25
- Technical
- Relative Strength Index (RSI)
- STTK 43.75
- PESI 40.98
- Support Level
- STTK $1.13
- PESI $10.10
- Resistance Level
- STTK $1.39
- PESI $10.79
- Average True Range (ATR)
- STTK 0.11
- PESI 0.51
- MACD
- STTK 0.00
- PESI 0.07
- Stochastic Oscillator
- STTK 18.18
- PESI 46.03
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About PESI Perma-Fix Environmental Services Inc.
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: Treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.